Soligenix (NASDAQ:SNGX) Posts Earnings Results

Soligenix (NASDAQ:SNGX) released its earnings results on Friday. The biopharmaceutical company reported ($0.12) earnings per share for the quarter, beating the consensus estimate of ($0.16) by $0.04, Zacks reports.

Soligenix Stock Performance

Shares of NASDAQ SNGX traded up $0.01 during mid-day trading on Friday, reaching $0.39. The company’s stock had a trading volume of 130,758 shares, compared to its average volume of 304,500. The stock has a 50-day moving average of $0.41 and a two-hundred day moving average of $0.81. The stock has a market capitalization of $5.81 million, a P/E ratio of -0.23 and a beta of 1.93. Soligenix has a 1-year low of $0.28 and a 1-year high of $6.23.

Institutional Trading of Soligenix

Large investors have recently bought and sold shares of the business. Banco BTG Pactual S.A. acquired a new stake in Soligenix in the 3rd quarter valued at about $54,000. Two Sigma Investments LP purchased a new position in Soligenix in the 3rd quarter worth approximately $102,000. Virtu Financial LLC purchased a new position in Soligenix in the 3rd quarter worth approximately $59,000. Armistice Capital LLC acquired a new position in shares of Soligenix during the 3rd quarter worth approximately $821,000. Finally, Geode Capital Management LLC boosted its holdings in shares of Soligenix by 88.8% during the 4th quarter. Geode Capital Management LLC now owns 80,401 shares of the biopharmaceutical company’s stock worth $108,000 after purchasing an additional 37,811 shares during the last quarter. Hedge funds and other institutional investors own 3.60% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Soligenix in a research report on Friday, July 17th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has an average rating of “Sell”.

About Soligenix

Soligenix, Inc is a clinical‐stage biopharmaceutical company focused on developing vaccines and therapeutics to address unmet medical needs in rare diseases and biodefense. The company leverages proprietary technologies to create novel vaccine adjuvants, small‐molecule innate defense regulators and photodynamic therapies aimed at improving patient outcomes in orphan indications and protecting public health against biological threats.

The company’s pipeline is organized into two core divisions.